This study is testing an investigational drug called BMS-986322 (the “study drug”) in adults with plaque psoriasis. The purpose of the study is to learn whether the study drug is safe and effective at different dose levels.

Study design
If you qualify and choose to participate in this study, you will:

– Take either the study drug (at one of three dose levels) or placebo* for 12 weeks
– Visit the study doctor 8 times for tests and procedures to assess your health and
your plaque psoriasis.
A computer will assign you at random (by chance) to a study group. You will have a 3 in 4 (75%) chance of being in a group that takes the study drug; you will have a 1 in 4 (25%) chance of being in the group that takes only placebo. You will not know which group you are in; the study doctor and staff also will not know.

Study periods
The study is split into three main stages (also known as “study periods”). These are briefly described here. The study doctor will explain them in more detail.

1. Screening (informed consent** followed by screening tests and procedures to find out if you qualify to participate in the study)
2. Study treatment (12 weeks of taking either the study drug or placebo)
3. Follow-up (final visit 30 days after study treatment ends)

* A placebo is a substance that looks like the study drug but contains no active
ingredients. Placebos help us make sure that any changes are due to the study drug and not another reason.
** During informed consent, the study will be explained to you. You will be able to ask any questions you may have about the study.

If you want to take part in the study, you will sign the informed consent form before any screening tests begin.